# A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

> **NCT07640451** · PHASE2 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 90 (estimated)

## Conditions studied

- COPD

## Interventions

- **DRUG:** HRS-9821 Inhalation Suspension
- **DRUG:** HRS-9821 Placebo Inhalation Suspension

## Key facts

- **NCT ID:** NCT07640451
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2026-10
- **Final completion:** 2026-11
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640451, "A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*